To investigate the ability of the tumor-targeting IL-4Rα-aptamer liposome-cytosine phosphate guanine oligodeoxynucleotides (CpG ODN) delivery system to introduce CpG into tumors and overcome immunosuppressive TME, Liu et al. [83] found that IL-4Rα-liposome-CpG therapy showed enhanced antitumor activity in CT26 tumor-bearing mice compared with the control group. This evidence concerns the gene IL4R and neoplasm.